SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease.

Brown, EE; Blauwendraat, C; Trinh, J; Rizig, M; Nalls, MA; Leveille, E; Ruskey, JA; Jonvik, H; Tan, MMX; Bandres-Ciga, S; et al. Brown, EE; Blauwendraat, C; Trinh, J; Rizig, M; Nalls, MA; Leveille, E; Ruskey, JA; Jonvik, H; Tan, MMX; Bandres-Ciga, S; Hassin-Baer, S; Brockmann, K; Infante, J; Tolosa, E; Ezquerra, M; Ben Romdhan, S; Benmahdjoub, M; Arezki, M; Mhiri, C; Hardy, J; Singleton, AB; Alcalay, RN; Gasser, T; Grosset, DG; Williams, NM; Pittman, A; Gan-Or, Z; Fernandez-Santiago, R; Brice, A; Lesage, S; Farrer, M; Wood, N; Morris, HR; International Parkinson Disease Genomics Consortium (IPDGC) (2021) Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease. Neurobiol Aging, 97. 148.e17-148.e24. ISSN 1558-1497 https://doi.org/10.1016/j.neurobiolaging.2020.07.002
SGUL Authors: Pittman, Alan Michael

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson's disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724) and meta-analyzed our data with previously published data (n = 754). VAMP4 is in close proximity to DNM3, and was associated with PD in a recent study, so it is possible that variants in this gene may be important. We also analyzed the effect of VAMP4 rs11578699 on LRRK2 penetrance. Our analysis of DNM3 in previously unpublished data does not show an effect on age at onset in LRRK2 p.G2019S carriers; however, the inter-study heterogeneity may indicate ethnic or population-specific effects of DNM3. There was no evidence for linkage disequilibrium between DNM3 and VAMP4. Analysis of sporadic patients stratified by the risk variant LRRK2 rs10878226 indicates a possible interaction between common variation in LRRK2 and VAMP4 in disease risk.

Item Type: Article
Additional Information: © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Genetic modifiers, Leucine-rich repeat kinase 2, Parkinsonism, Parkinson’s disease, Parkinson's disease, Genetic modifiers, Parkinsonism, Leucine-rich repeat kinase 2, 1103 Clinical Sciences, 1109 Neurosciences, Neurology & Neurosurgery
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Neurobiol Aging
ISSN: 1558-1497
Language: eng
Dates:
DateEvent
January 2021Published
13 July 2020Published Online
3 July 2020Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
J-1101Parkinson's UKhttp://dx.doi.org/10.13039/501100000304
H-1703Parkinson's UKhttp://dx.doi.org/10.13039/501100000304
MR/N026004/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
202903/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 32873436
Web of Science ID: WOS:000600846900027
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/112874
Publisher's version: https://doi.org/10.1016/j.neurobiolaging.2020.07.002

Actions (login required)

Edit Item Edit Item